A poster featuring a post-hoc exploratory analysis of measures of thalamic volume from RADIANCE was presented September 11, 2019, at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
Ozanimod, an oral immunomodulatory drug now under FDA review for the treatment of relapsing multiple sclerosis (MS), appears to be more effective than interferon β-1a (Avonex) at slowing disease activity, based on an established brain measure taken during phase 3 of the RADIANCE trial.
A poster featuring a post-hoc exploratory analysis of measures of thalamic volume (TV) from RADIANCE was presented September 11, 2019, at ECTRIMS 2019,1 the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
The study authors noted that whole brain volume is a known measure of disease progression in relapsing MS, yet “evidence of the relationship between thalamic volume and disease activity in prospective, multicenter studies is sparse.” TV has been studied for years as a predictor of cognitive speed; a 2001 paper by Van Der Werf, et al, discussed how a decrease in TV “was apparent before the onset of loss of volume of the total brain.”2
Relapsing MS occurs when inflammation damages myelin, a fatty substance that insulates nerve cells, and thus allows interference with nerve impulses, triggering MS symptoms. Ozanimod works by selectively binding 2 receptors—the sphingosine 1-phosphate (S1PR1) and the S1PR5 receptors, which keeps immune cells from entering the brain and blocks inflammation of the central nervous system, so this inflammatory process does not occur.
The investigational therapy has been studied in 2 doses, 0.5 mg and 1.0 mg, in a pair of phase 3 trials, SUNBEAM and RADIANCE. The SUNBEAM trial featured 3 study arms: 1 arm each of patients taking the 2 doses of ozanimod and another taking interferon β-1a; full results of the 12-month study, first presented in 2017, were published last week in Lancet Neurology and show that ozanimod was well-tolerated and demonstrated a significantly lower relapse rate than interferon β-1a.3
RADIANCE was a 2-part trial to assess safety and efficacy of ozanimod compared with placebo. In the first part, 258 patients were randomly assigned to take 0.5 mg or 1.0 mg of the study drug or placebo once daily for 24 weeks. Patients taking ozanimod had fewer brain lesions after week 12, as measured by magnetic resonance imaging (MRI), as well as fewer relapses. During the second, open-label phase, 249 patients continued in the trial for 96 weeks. All those given ozanimod in the first phase stayed on their current dose, while those who had taken placebo were randomly assigned to either 0.5 mg or 1.0 mg. Both groups were free of disease activity and brain lesions after 24 months. Patients from the original placebo group had a large drop in relapses once they started taking ozanimod.4
RADIANCE offered an opportunity use TV measures taken at baseline to compare the effectiveness of the study drug, ozanimod, against interferon β-1A. Data presented Wednesday found that in patients with relapsing MS, smaller baseline TV is a sign of a higher disease burden and increased disease activity after 2 years, compared with those with higher baseline TV.1 Specifically, the data presented Wednesday showed:
US and European regulators are evaluating data from the multicenter, randomized, double-blind phase 2/3 RADIANCE and the phase 3 SUNBEAM trials, which were submitted in March. FDA accepted Celgene’s application for ozanimod June 6, 2019, and a decision is expected March 25, 2020.
References
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen